Macitentan Use in an Idiopathic Pulmonary Fibrosis Clinical Study

Update Il y a 3 ans
Reference: NCT00903331

Woman and Man

Extract

The AC-055B201/MUSIC study is a Phase II study, comparing one dose of ACT-064922 (macitentan) 10 mg with placebo in patients with idiopathic pulmonary fibrosis (IPF). The main study objective is to demonstrate that macitentan positively affects the forced vital capacity (FVC) in comparison with placebo in patients with idiopathic pulmonary fibrosis (IPF). The secondary objectives are to evaluate the effect of macitentan on the time to disease worsening or death in patients with IPF, and to evaluate the benefit/risk profile of macitentan in the treatment of patients with IPF.


Inclusion criteria

  • Idiopathic pulmonary fibrosis


Links